[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100589038":3},{"organization":4,"armGroups":7,"interventions":14,"overallOfficials":19,"centralContacts":20,"locations":30,"responsibleParty":46,"collaborators":19,"id":48,"slug":19,"hasResults":49,"nctId":50,"briefTitle":51,"officialTitle":52,"acronym":53,"eligibilityCriteria":54,"healthyVolunteers":49,"sex":55,"minAge":56,"maxAge":19,"enrollmentInfo":57,"targetDuration":19,"studyType":60,"phases":61,"briefSummary":63,"conditions":64,"keywords":67,"overallStatus":33,"whyStopped":19,"lastUpdateSubmitDate":71,"lastUpdatePostDateStruct":72,"startDateStruct":75,"completionDateStruct":77,"leadSponsor":79,"locationsCount":80},{"fullName":5,"class":6},"Peking Union Medical College Hospital","OTHER",[8],{"label":9,"type":10,"description":11,"interventionNames":12},"68Ga-NYM096 PET\u002FCT","EXPERIMENTAL","Each patient will receive one dose of 68Ga-NYM096 by intravenous route. Dedicated whole-body PET\u002FCT imaging will be performed.",[13],"Diagnostic Test: 68Ga-NYM096 PET\u002FCT",[15],{"type":16,"name":9,"description":17,"armGroupLabels":18,"otherNames":19},"DIAGNOSTIC_TEST","Participants will be administered a single, intravenous bolus of 68Ga-NYM096 The recommended administered activity of 68Ga-NYM096 is 1.8-2.2 MBq per kilogram bodyweight, subject to variation that may be required owing to variable elution efficiencies obtained during the lifetime of the 68Ga \u002F 68Ga generator.\n\nThe CT and PET imaging session will begin approximately 45 to 75 minutes after 68Ga-NYM096 administration.",[9],null,[21,26],{"name":22,"role":23,"phone":24,"phoneExt":19,"email":25},"Li Huo, MD","CONTACT","+86 18612672038","huoli@pumch.cn",{"name":27,"role":23,"phone":28,"phoneExt":19,"email":29},"Wenjia Zhu, MD","+86 18614080164","zhuwenjia_pumc@163.com",[31],{"facility":32,"status":33,"city":34,"state":19,"zip":35,"country":36,"cosmosGeoPoint":37,"geoPoint":42,"contacts":43},"Peking Union Medical College","RECRUITING","Beijing","100730","China",{"type":38,"coordinates":39},"Point",[40,41],116.39723,39.9075,{"lat":41,"lon":40},[44],{"name":45,"role":23,"phone":19,"phoneExt":19,"email":19},"Li Huo",{"type":47,"investigatorFullName":19,"investigatorTitle":19,"investigatorAffiliation":19,"oldNameTitle":19,"oldOrganization":19},"SPONSOR","100589038",false,"NCT06949215","68Ga-NYM096 PET\u002F CT for the Detection of ccRCC in Presurgical Patients With Complex Cystic Renal Leision","68Ga-NYM096 PET\u002F CT for the Detection of Clear Cell Renal Cell Carcinoma in Presurgical Patients With Complex Cystic Renal Leision","NYCRCCL","Inclusion Criteria:\n\n1. Age ≥ 18 y\n2. Presence of complex renal cyst (Bosniak category II or higher)\n3. Scheduled for surgical resection of renal mass (partial or total nephrectomy, open, laparoscopic, or robot-assisted technique)\n4. Expected survival of at least 3 months\n5. ECOG ≤ 2\n6. Written informed consent provided for participation in the trial\n7. In the opinion of investigator, willing and able to comply with required study procedures.\n\nExclusion Criteria:\n\n1. On VEGF TKI treatment less than 1 week before 68Ga-NYM096 PET\u002FCT. TKI is known to affect girentuximab binding in patients with ccRCC and is expected to have the same effect on 68Ga-NYM096. If patients were on VEGF TKI treatment, such as sunitinib, sorafenib, cabozantinib, pazopanib, or lenvatinib, a washout of one week before 68Ga-NYM096 PET\u002FCT is required.\n2. Intercurrent medical condition that renders the patient ineligible for surgery.\n3. Pregnancy or breastfeeding.\n4. Severe claustrophobia.","ALL","18 Years",{"count":58,"type":59},70,"ESTIMATED","INTERVENTIONAL",[62],"PHASE2","This is a prospective, single-center, single-arm, diagnostic phase 2 study aimed at evaluating the sensitivity and specificity of 68Ga-NYM096 PET\u002FCT in detecting clear cell renal cell carcinoma (ccRCC) in patients with complex renal cysts who are scheduled for surgical resection. The study will use histopathological diagnosis as the reference standard to assess the diagnostic accuracy of 68Ga-NYM096 PET\u002FCT in identifying ccRCC within operable complex renal cystic lesion. The findings will provide critical insights into the performance of 68Ga-NYM096 PET\u002FCT as a non-invasive imaging tool for the preoperative detection of ccRCC in this patient population.",[65,66],"ccRCC","Complex Renal Cyst",[68,69,70],"PET\u002FCT","complex renal cyst","68Ga-NYM096","2026-05-21",{"date":73,"type":74},"2026-05-26","ACTUAL",{"date":76,"type":74},"2025-05-01",{"date":78,"type":59},"2027-07-01",{"name":5,"class":6},1]